tbuckley/cabot-search huggingface dataset:
Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes
Authors: Eleftheria Lamprianidou, Chrysoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, Anastasia Filia, Stamatia Laidou, Theodoros P. Vassilakopoulos, Sotirios Papageorgiou, Vassiliki Pappa, Athanasios Galanopoulos, Nora-Athina Viniou, Evangelia Nakou, Anastasia Hadzidimitriou, George Kassiotis, Elli Papaemmanuil, Ioannis Mitroulis, Ioannis Kotsianidis
Journal: Blood (2019)
RARE-36. BORTEZOMIB WOKE UP A PATIENT WITH ANTI-NMDA RECEPTOR ENCEPHALITIS REFRACTORY TO STANDARD THERAPY AND LONG TERM FOLLOW-UP
Authors: Kong Xiao-Tang, Leonid Groysman, Cyrus Dastur, Beverly Fu, Daniela Bota
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE To report a case with refractory NMDA encephalitis in comatose for 18 months, who was treated successfully with bortezomib. BACKGROUND Anti-NMDA encephalitis is a rare autoimmune encephalitis. Standard therapy include corticosteroid, IVIG or plasma exchange, cyclophosphamide, rituximab, and tumor removal. Refractory cases are very severe and often stay in ICU on ventilation for several months to years. Bortezomib for the treatment of refractory anti-NMDA receptor encephalitis was reported. We have applied the treatment to our refractory case and successfully woke up the patient. And we have followed up the patient for 3 years. METHODS Case report. RESULTS A 40 yo male was diagnosed as anti-NMDA encephalitis. Standard therapy was applied. After stabilization, the patient was eventually discharged to ICU at a long term care subacute hospital. The patient was brought back for more Rituxan or steroid or IVIG therapy. The condition had not improved at all. Eighteen months in comatose, the patient had worsening NMDA titer in CSF to 1:640. Decision was made to start bortezumib as reported with modification: 1.3 mg/m2 bortezomib were administered on days 1, 8, 11 and 14 and allowed two weeks off therapy. After first cycle, the patent started to talk first word “hurt.” After 6 cycles, the patient sat up and started riding bicycles for physical therapy. The NMDA titer in CSF was reduced to 1:40 at the end of 6 cycles. One year later, the patent stood up and ambulated with a walker. One and half year later, the patient walks without assistance and his speech and cognition have significantly improved with good communication with family members and staff. CONCLUSIONS Proteasome inhibitor bortezomib might be considered to be the third line therapy as early as possible if the first line and second line are ineffective to treat anti-NMDA receptor encephalitis.
The Wolff-Parkinson-White Syndrome
Authors: Norman H. Boyer
Journal: New England Journal of Medicine (1946)

TO THOSE with extensive electrocardiographic experience, especially if it includes a large proportion of young adults, the finding of the pattern of a short PR interval and a prolonged QRS complex comes as no great surprise. That it is not a rare occurrence, as might be concluded from the many papers in the literature reporting one or two cases, needs to be emphasized, because this combination is still all too frequently misinterpreted as being of clinical significance. Such misinterpretation might be considered negligible if the electrocardiographic findings occurred but rarely. On the other hand, if the pattern is as frequent . . .
Pancreatic Iron and Glucidic Metabolism in Thalassemia Major
Authors: Alessia Pepe, Laura Pistoia, Saveria Campisi, Roberto Sarli, Piera Giovangrossi, Giulia Guerrini, Roberto Mattei, Aurelio Maggio, Domenico Visceglie, Valentina Carrai, Giuseppe Peritore, Vincenzo Positano, Antonella Meloni
Journal: Blood (2019)
DDIS-37. SMALL MOLECULE AUTOPHAGY ACTIVATORS IN GROWTH INHIBITION OF GLIOBLASTOMA
Authors: Ariana Waters, Elmar Nurmammadov, Natsuko Nomura, Ivan Babic, Santosh Kesari, Venkata Yenugonda
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is one of the most lethal human tumors, and despite considerable advances in multimodality treatments consisting of surgical removal, radiation and chemotherapy, overall survival is 14 to 16 months after diagnosis. Therefore, there is a need to target non-apoptotic death pathways and inhibit pro-survival signaling mechanisms that contribute to both tumorigenesis and treatment resistance. Depending on tumor type and environment, autophagy modulation plays an important role in tumor cell survival and inhibition pathways. Increasing evidence supports that chemical modulation of autophagy inhibition and activation holds a therapeutic potential and these studies have led to the initiation of multiple clinical trials combining chemotherapeutic agents and autophagy inhibitors and activators for various cancer types. However, recent studies have also demonstrated a therapeutic potential for enhancers of autophagy in GBM. This clearly demonstrates the need for further investigation into the autophagy induced mechanism of GBM, and the development of better treatments. We have identified a new chemical entity VMY-BC-1 that showed promising effects in both serum and patient-derived glioma cell lines. Drug target engagement studies identified an autophagy induction protein, UNC-51 like kinase 1 (ULK1), as the main target of VMY-BC-1, in which VMY-BC-1 covalently bound to the protein’s active pocket and increased ULK1 phosphorylation.ULK1 is a component of the ULK1 complex (ULK1-ATG13-FIP200) that is essential for inducing autophagy, a lysosome-dependent mechanism of intracellular degradation for maintaining cellular homeostasis. Additionally, our molecule cross talks to the apoptotic and DNA damage pathways, which could potentially overcome treatment resistance.VMY-BC-1 is orally bioavailable, brain penetrant, and inhibits cell invasion and tumor growth in GBM flank models, making this small molecule an ideal candidate for further development. We hypothesize that activating ULK1-modulated autophagy will be a therapeutic strategy for GBM growth inhibition
Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes
Authors: Yue Wei, Monica Cabrero, Yu Jia, Hong Zheng, Hui Yang, Zhihong Fang, Zach Bohannan, Rui Chen, Hui Wang, Simona Colla, Xia Wang, Guillermo Garcia-Manero
Journal: Blood (2014)
Diseases of the Cardiovascular System (Surgical)
Authors: C A Hufnagel
Journal: Annual Review of Medicine (1956)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe, killing more than 4 million people and causing a severe economic crisis. ...Read More
Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities
Authors: Naoto Takahashi, Tomoko Yoshioka, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Tomoki Naoe, Itaru Matsumura
Journal: Blood (2019)
Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1
Authors: Jun Zhu, Grzegorz Nowakowski, Qingyuan Zhang, Joshua Brody, Xiuhua Sun, Joseph Maly, Yuqin Song, Yongping Song, Jennifer Kimberly Lue, Wen Luo, Lei Zhang, Isabel Han, Manoj Jivani, Young Liu, Ling Li, Joan Sun, Stephen D. Smith
Journal: Blood (2019)
Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany
Authors: Stephane De Botton, Joseph M Brandwein, Eytan M. Stein, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, Peter Paschka, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner
Journal: Blood (2019)
Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults
Authors: Pierre Peterlin, Jacques Delaunay, Thierry Guillaume, Thomas Gastinne, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Amandine Le Bourgeois, Eolia Brissot, Laurence Lode, Steven Le Gouill, Philippe Moreau, Mohamad Mohty, Patrice Chevallier
Journal: Blood (2014)
Abstract 13403: What Characterizes the Patients Who Develop Repeated or Persistent Hyperkalaemia? a Population-Based Laboratory Study of Potassium Trajectories in Patients With Chronic Heart Failure
Authors: Reimar W Thomsen, Sia K Nicolaisen, Eirini Palaka, Pål Hasvold, Lars Pedersen, Kasper Adelborg, Henrik T Sørensen
Journal: Circulation (2018)

Introduction: Hyperkalaemia (HK) defined as blood potassium (K+) >5.0 mmol/L is common among patients with chronic heart failure (CHF) and associated with adverse outcomes. Little is known about th...
Information and Communication Technology Applied to Continuing Quality Improvement for the Care and Cure of Childhood Severe Hematological Disorders in India
Authors: Rajat Kumar Agarwal, Rakesh Dhanya, Ankita Kumari, Lalith Parmar, Amit Sedai, Stalin Ramprakash, C P Raghuram, Pallavi Mehta, Deepa Trivedi, Shruthi Jayapal, Sandeep S, Lawrence Faulkner
Journal: Blood (2019)
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Authors: Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist, Toni K. Choueiri, Saby George, Brett G.M. Hughes, Matthew D. Hellmann, Dale R. Shepard, Brian I. Rini, Shivaani Kummar, Amy M. Weise, Matthew J. Riese, Ben Markman, Leisha A. Emens, Daruka Mahadevan, Jason J. Luke, Ginna Laport, Joshua D. Brody, Leonel Hernandez-Aya, Philip Bonomi, Jonathan W. Goldman, Lyudmyla Berim, Daniel J. Renouf, Rachel A. Goodwin, Brian Munneke, Po Y. Ho, Jessica Hsieh, Ian McCaffery, Long Kwei, Stephen B. Willingham, Richard A. Miller
Journal: Cancer Discovery (2019)

Abstract Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial with a small-molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling in vivo. In a cohort of 68 patients with renal cell cancer (RCC), we also observe clinical responses alone and in combination with an anti–PD-L1 antibody, including subjects who had progressed on PD-1/PD-L1 inhibitors. Durable clinical benefit is associated with increased recruitment of CD8+ T cells into the tumor. Treatment can also broaden the circulating T-cell repertoire. Clinical responses are associated with an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-1/PD-L1 that restricts antitumor immunity. Significance: This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent and anti–PD-L1 combination therapy in patients with refractory RCC. Responding patients possess an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. See related commentary by Sitkovsky, p. 16. This article is highlighted in the In This Issue feature, p. 1
Association of Intestinal Alkaline Phosphatase With Necrotizing Enterocolitis Among Premature Infants
Authors: Maya Heath, Rebecca Buckley, Zeromeh Gerber, Porcha Davis, Laura Linneman, Qingqing Gong, Brian Barkemeyer, Zhide Fang, Misty Good, Duna Penn, Sunyoung Kim
Journal: JAMA Network Open (2019)

Necrotizing enterocolitis (NEC) in preterm infants is an often-fatal gastrointestinal tract emergency. A robust NEC biomarker that is not confounded by sepsis could improve bedside management, lead to lower morbidity and mortality, and permit patient selection in randomized clinical trials of possible therapeutic approaches.
Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans
Authors: Christine Rivat, Natalia Izotova, Rachel Richardson, Danilo Pellin, Rachael Hough, Robert Wynn, Kim Champion, Andre Lopes, Sara Ghorashian, Martin Pule, Adrian J. Thrasher, Luca Biasco, Persis J Amrolia
Journal: Blood (2019)
CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
Authors: Geoffrey L. Uy, Tapan M. Kadia, Wendy Stock, Jonathan E Brammer, Osnat Bohana-Kashtan, Abi Vainstein, Ella Sorani, Hemda Chen, John F. DiPersio, Daniel C. Link
Journal: Blood (2019)
CBMT-13. 3DEP SYSTEM TO TEST THE ELECTRICAL PROPERTIES OF DIFFERENT CELL LINES AS PREDICTIVE MARKERS OF OPTIMAL TUMOR TREATING FIELDS (TTFIELDS) FREQUENCY AND SENSITIVITY
Authors: Moshe Giladi, Einav Zeevi, Karnit Gotlib, Cornelia Wenger, Ariel Naveh, Ze’ev Bomzon, Eilon Kirson, Uri Weinberg, Adrian Kinzel, Yoram Palti
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Tumor Treating Fields (TTFields; approved anti-neoplastic treatment modality) are delivered via application of low intensity, intermediate frequency, alternating electrical fields. The electrical properties of cells (eg, permittivity and conductivity) determine the optimal TTFields frequency that would elicit the greatest cell count reduction. Currently, no predictive markers exist to determine TTFields response and optimal frequency for individual patient application. The study goal was to evaluate the correlation between electrical properties of cells and TTFields’s optimal frequency and sensitivity. The 3DEPTM reader (LabTech) determines cellular electrical properties, including permittivity and conductivity, by using dielectrophoresis (DEP) force. DEP is a physical effect that generates a force on polarizable particles, such as cells, subjected to non-uniform electric fields. METHODS Utilizing the 3DEP reader, baseline electrical properties (permittivity and conductivity) of 17 cell lines from different tumor-types were determined. Curves were analyzed using 2-way ANOVA. The optimal TTFields frequency of each cell line was determined by evaluating TTFields cytotoxicity at various frequencies using the inovitroTM system. Electrical properties of each cell line were compared with the optimal TTFields frequency and sensitivity. RESULTS Significant differences (P&lt; 0.001) were demonstrated between the lower frequency range of the 3DEP curves that correspond to cellular membrane capacitance at TTFields optimal frequencies of 150 kHz (9 cell lines) and 200 kHz (8 cell lines). Also, membrane capacitance was a good predictor of TTFields sensitivity based on curve differences within the low-frequency range. CONCLUSIONS These results demonstrate that cell membrane capacitance correlates with TTFields optimal frequency and sensitivity. Based on these data, there is a strong rational to further explore the potential of measuring the electrical properties of cells as predictive markers to help determine the optimal TTFields frequency for individual patient application and to identify ideal treatment-responders to TTFields.
Proteasome-Dependent Degradation of Guanosine 5′-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus
Authors: JianXu, YongWu, PingSong, MiaoZhang, ShuangxiWang, Ming-HuiZou
Journal: Circulation (2007)

Background— Tetrahydrobiopterin (BH4) deficiency is reported to uncouple the enzymatic activity of endothelial nitric oxide synthase in diabetes mellitus. The mechanism by which diabetes actually leads to BH4 deficiency remains elusive. Here, we demonstrate that diabetes reduced BH4 by increasing 26S proteasome-dependent degradation of guanosine 5′-triphosphate cyclohydrolase I (GTPCH), a rate-limiting enzyme in the synthesis of BH4, in parallel with increased formation of both superoxide and peroxynitrite (ONOO−). Methods and Results— Exposure of human umbilical vein endothelial cells to high glucose concentrations (30 mmol/L D-glucose) but not to high osmotic conditions (25 mmol/L L-glucose plus 5 mmol/L D-glucose) significantly lowered the levels of both GTPCH protein and BH4. In addition, high glucose increased both the 26S proteasome activity and the ubiquitination of GTPCH. Inhibition of the 26S proteasome with either MG132 or PR-11 prevented the high glucose–triggered reduction of GTPCH and BH4. Ex...
HLA-Mismatched Stem Cell Microtransplantation Compared to Matched-Sibling Donor Transplantation for Acute Myeloid Leukemia in First Complete Remission
Authors: Limin Liu, Huiying Qiu, XiaoWen Tang, Yue Han, Miao Miao, Chengcheng Fu, Zhengming Jin, Mingqing Zhu, Depei Wu
Journal: Blood (2016)
Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies
Authors: Aileen Kelly, Daniel W Robbins, May Tan, Austin Tenn-McClellan, Joel McIntosh, Jeffrey Wu, Zef Konst, Daisuke Kato, Luz Perez, Jennifer Tung, Anna Kolobova, Timothy Ingallinera, Jenny McKinnell, Dahlia Weiss, Mark Noviski, Jordan Ye, Ge Peng, Mario Cardozo, Jeff Mihalic, Steve Basham, Ryan Rountree, Dane E Karr, Neil Bence, Christoph W Zapf, Arthur T Sands
Journal: Blood (2019)
Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?
Authors: Vera Adema, Cassandra M Kerr, Wencke Walter, Stephan Hutter, Yasunobu Nagata, Hassan Awada, Sunisa Kongkiatkamon, Christina A. Snider, Milo Co, Rainey Magdalena, Arda Durmaz, Manja Meggendorfer, Aziz Nazha, Jacob Scott, Hetty E. Carraway, Mikkael A. Sekeres, Francesc Sole, Torsten Haferlach, Valeria Visconte, Jaroslaw P. Maciejewski
Journal: Blood (2019)
Primary Prophylaxis with Pegfilgrastim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Nation-Wide, Propensity Score Based Analysis
Authors: Kensuke Matsuda, Taisuke Jo, Masashi Miyauchi, Kazuhiro Toyama, Kumi Nakazaki, Hideo Yasunaga, Mineo Kurokawa
Journal: Blood (2019)
Genome-Wide microRNA Expression Profiling in Molecular Subgroups of Peripheral T-Cell Lymphoma Identified Role of Mir-126 in T-Cell Lymphomagenesis
Authors: Waseem Lone, Alyssa Bouska, Tyler Herek, Catalina Amador, Mallick Saumyaranajn, Yu Jiayu, Tayla Heavican, Stefano A. Pileri, Timothy McKeithan, Wing C. Chan, Javeed Iqbal
Journal: Blood (2019)
Vaccine Against Poliomyelitis
Authors: J. Trueta
Journal: BMJ (1957)

Because of heavy pressure on our space, correspondents are asked to keep their letters short.Vaccine Against' Poliomyelitis SIR,-YOur issue of June 1 may be kept in gilded covers, for in it the report of the Poliomyelitis Vaccines Committee of the Medical Research Council is published (p. 1271),and, with the cool objectivity of a scientific survey of this nature, the dawn is announced of the day which will see new epi- demics of paralytic poliomyelitis no more.Among the 148,684 children from 1 to 9 years of age who received two injections of the British-prepared (Glaxo) vaccine within less than three weeks 2.7 per 100,000 suffered from paralytic poliomyelitis, whereas among the non-vaccinated over 14 per 100,000 were affected.These figures from the well-planned trial may be com- pared with those included in the report on the 1956 polio- myelitis outbreak in Chicago' submitted by the Chicago Board of Health.Both the British and the Chicago analyses show that no paralytic poliomyelitis occurring in vaccinated children had any connexion with the vaccination, as paralysis did not occur in the inoculated limb.From June 28 to October 4, 1956, Chicago had 1,111 cases of confirmed poliomyelitis of which 835 were paralytic.During the spreading of the epidemic vaccination was intensified, and by the first week of October, of the 1,150,000 children in Chicago up to 191 years of age, 125,000 had had no inocula-
Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria, Australia
Authors: Danit Maor, Claire M. Vajdic, Simon Cumming, Vanessa Fahey, Harini R. Bala, Victoria Snaidr, Sarah Brennand, Michelle S.Y. Goh, Alvin H. Chong
Journal: Journal of the American Academy of Dermatology (2019)
Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
Authors: Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan, Michael Dougan
Journal: Journal for ImmunoTherapy of Cancer (2019)

Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically active glucocorticoids. Endoscopy can stratify patients by the severity of mucosal inflammation, including identifying patients with colitis in the absence of visible mucosal changes: microscopic colitis. Whether patients with CPI microscopic colitis could be managed differently from colitis with more severe mucosal involvement is unclear. The objective of this study was to describe outcomes in CPI microscopic colitis focusing on the response to first line treatment with budesonide.We evaluated data from a retrospective cohort from a single-center large academic hospital. The participants were all adult patients evaluated by endoscopy for suspected CPI enterocolitis between 3/2017 and 3/2019. The exposures were: Mayo Endoscopic Score (range 0-3). The subset was: oral budesonide, maximum dose 12 mg daily, administered minimum of 5 weeks. The main outcomes and measures were: Primary: time from first CPI exposure to first glucocorticoid use; use of systemic glucocorticoids; time from symptom onset to resolution; continuation of CPI therapy; number of additional CPI infusions received. Secondary: admissions for symptom control; novel irAE development; need for second-line immunosuppression; oncologic outcomes.We identified 38 patients with biopsy confirmed CPI enterocolitis, 13 in the microscopic colitis cohort, and 25 in the non-microscopic colitis cohort. Budesonide use was higher in the microscopic colitis cohort (12/13 vs 3/25, p < 0.001), and systemic glucocorticoid use was higher in non-microscopic colitis (22/25 vs. 3/13, p < 0.001). Time from symptom onset to resolution did not differ. Microscopic colitis patients more frequently remained on CPI after developing (entero)colitis (76.9% vs 16.0%, p < 0.001). Microscopic colitis patients tolerating further CPI received, on average, 4.2 CPI infusions more than non-microscopic colitis patients tolerating CPI (5.8 vs 1.6, p = 0.03). Microscopic colitis was associated with increased time-to-treatment-failure (HR 0.30, 95% CI 0.14-0.66) and progression-free survival (HR 0.22, 95% CI 0.07-0.70).Gastrointestinal mucosal inflammation without visible mucosal injury is a distinct, prevalent CPI enterocolitis subset that can be diagnosed by endoscopy. First-line budesonide appears effective in controlling "microscopic colitis" symptoms and prolonging immunotherapy duration. These findings present a compelling rationale for routine endoscopic evaluation of suspected CPI enterocolitis and suggest an alternative glucocorticoid-sparing treatment strategy for a subset of such patients.
With Equal Access, African Americans with Non-del17p Multiple Myeloma Have Superior Overall Survival, but del17p Still Carries Poor Prognosis across Race: A VA Study
Authors: Anusha Munjuluri, Nathanael Fillmore, Diana Cirstea, Hassan Yameen, Sarvari Venkata Yellapragada, Ifeorah Chizoba, Nhan Do, Mary Brophy, Nikhil C. Munshi
Journal: Blood (2019)